Modernatx, Inc.

Aveo Pharmaceuticals, Inc.

Ailin Bai

Joshua P Frederick

Kerry Benenato

Stephen G Hoge

Vladimir Presnyak

Ellalahewage Sathyajith Kumarasinghe

Iain McFadyen

Susannah Hewitt

Ting Chen

William M Winston, Jr

Jeno Gyuris

Solly Weiler

Zhigang Weng

Maria Isabel Chiu

Laura L Poling

Lorena Lerner

Sandra Abbott

Qing Liu

Nianjun Tao

Kristan Meetze

William M Winston

Laura Poling

Iain Mcfadyen

Lain Mcfadyen

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Anti-GDF-15 antibodies

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.

Methods of using OX40 ligand encoding polynucleotides

The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.

mRNA combination therapy for the treatment of cancer

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36&#x3b3; (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).

Combinations of mRNAs encoding immune modulating polypeptides and uses thereof

The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.

Polynucleotides encoding interleukin-12 (IL12) and uses thereof

MRNA combination therapy for the treatment of cancer

Growing community of inventors

Newton, MA, United States of America

Ailin Bai